Pulmonary Disease Doctors in Lynchburg, VA Accepting Medicare

8 Pulmonary Disease doctors found. Showing 1 - 8

Joseph B Khoury, M.D. Internal Medicine - Pulmonary Disease Medicare: May Accept Medicare Assignments Practice Location: 2011 Tate Springs Rd, Lynchburg, VA 24501 Phone: 434-947-3963    Fax: 434-947-5935

Lisa B Geier, N.P. Internal Medicine - Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1501 Lakeside Dr, Lynchburg, VA 24501 Phone: 434-544-8357    Fax: 434-544-8131

Dr. Prema Madhuri Pamireddy, M.D. Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2011 Tate Springs Rd, Lynchburg, VA 24501 Phone: 434-947-3963    Fax: 434-947-5935

Sarah C Hellewell, M.D. Internal Medicine - Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 2011 Tate Springs Rd, Lynchburg, VA 24501 Phone: 434-947-3963    Fax: 434-947-5935

John F Plankeel, M.D. Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2011 Tate Springs Rd, Lynchburg, VA 24501 Phone: 434-947-3963    Fax: 434-947-5935

Michael G. Milam, M.D. Internal Medicine - Pulmonary Disease Medicare: May Accept Medicare Assignments Practice Location: 2011 Tate Springs Rd, Lynchburg, VA 24501 Phone: 434-947-3963    Fax: 434-947-5935

Albert M Baker, M.D. Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2011 Tate Springs Rd, Lynchburg, VA 24501 Phone: 434-947-3963    Fax: 434-947-5935

Carol H Driskill, N.P. Internal Medicine - Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 2011 Tate Springs Rd, Lynchburg, VA 24501 Phone: 434-947-3963    Fax: 434-947-5935

News Archive

NPS Pharmaceuticals prices 9,000,000 shares of common stock at $5.50 per share

NPS Pharmaceuticals, Inc. today announced that it has priced an underwritten public offering of 9,000,000 shares of its common stock at a price to the public of $5.50 per share. Net proceeds, after estimated underwriting discounts and commissions and estimated expenses, will be approximately $46.2 million.

Cannabis compound inhibits SARS-CoV-2 replication in human lung cells

Researchers in the United States have conducted a study showing that a cannabis plant compound inhibited infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human lung cells.

HHS announces $1 billion in Recovery Act awards for construction, repair and renovation of research facilities

U.S. Department of Health and Human Services Secretary Kathleen Sebelius today announced one billion dollars of American Recovery and Reinvestment Act funds have been awarded to construct, repair and renovate scientific research laboratories and related facilities across the country. The National Institutes of Health (NIH) National Center for Research Resources (NCRR) administered the grants, which are expected to create or sustain jobs nationwide and to help foster scientific advances that may lead to improved human health.

TD2 and Oncoholdings partner to accelerate development of superior oncology agents

TGen Drug Development (TD2) and Oncoholdings Inc. announced today a partnership agreement that could lead to the prompt development of new anti-cancer agents.

Read more Medical News

› Verified 2 days ago